文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

宫颈癌与子宫内膜癌调强放疗后骨盆功能不全骨折的前瞻性II期研究

Incidence of and Risk Factors for Pelvic Insufficiency Fracture in Patients With Cervical or Endometrial Cancer Treated With Intensity Modulated Radiation Therapy: A Single-Center, Prospective, Phase II Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-07-29

该前瞻性II期临床试验评估了113例接受盆腔调强放疗的宫颈癌或子宫内膜癌患者,中位随访26个月时骨盆功能不全骨折发生率为29.2%。绝经状态和放疗前总I型前胶原氨基端前肽≥55 ng/mL是独立危险因素,骨折多为多发病灶且症状轻微。

要点

  • 盆腔调强放疗后骨盆功能不全骨折发生率为29.2%,中位发生时间8.6个月。
  • 绝经状态和放疗前总I型前胶原氨基端前肽≥55 ng/mL是独立危险因素。
  • 骨折以骶骨和髂骨为主,多发病灶常见,症状多轻微,病灶面积随时间变化。

核心结论

  • 骨盆功能不全骨折是宫颈癌和子宫内膜癌盆腔调强放疗后常见的晚期并发症。
  • 绝经状态和放疗前总I型前胶原氨基端前肽≥55 ng/mL是骨盆功能不全骨折发生的独立预测因素。

研究设计与样本

  • 前瞻性II期临床试验,纳入2016至2022年单中心接受盆腔调强放疗的113例宫颈癌或子宫内膜癌患者。
  • 骨盆功能不全骨折由2名资深放射科医生基于盆腔磁共振成像诊断,并通过及时随访验证。

主要发现

  • 中位随访26个月(范围14-41个月),骨盆功能不全骨折发生率为29.2%。
  • 骨盆功能不全骨折中位发生时间为调强放疗后8.6个月(范围3.5-13.5个月)。
  • 初诊时中位病灶数为2个(范围1-3个),57.6%有症状,66.7%为多发病灶(≥2个)。
  • 骶骨(33.3%)和髂骨(28.2%)主要受累,中位病灶面积1.97 cm²(范围0.92-3.28 cm²)。
  • 放疗后病灶总面积达峰值的中位时间为15.8个月(范围9.7-22.6个月),当时中位病灶数为4个(范围3-5个)。

关键数值与推荐

  • 绝经状态与骨盆功能不全骨折独立相关(OR 18.853;95% CI 1.396-254.580;P = .027)。
  • 放疗前总I型前胶原氨基端前肽浓度≥55 ng/mL与骨盆功能不全骨折独立相关(OR 4.743;95% CI 1.257-17.915;P = .022)。
  • 骨盆功能不全骨折面积(P = .134)和病灶数(P = .157)与骨盆骨痛严重程度无关。
  • 骨盆功能不全骨折发生与骨盆骨剂量体积参数、临床因素(年龄>53岁、治疗类型、骨质疏松)或其他生化标志物均无显著关联(均P > .05)。

临床怎么用

  • 对接受盆腔调强放疗的宫颈癌或子宫内膜癌患者,尤其是绝经后或放疗前总I型前胶原氨基端前肽≥55 ng/mL者,应警惕骨盆功能不全骨折。
  • 放疗后早期至1年左右需关注骨盆功能不全骨折的多发病灶及病灶面积随时间的变化,即使症状轻微也应考虑影像学评估。

局限性

  • 单中心研究,样本量113例,随访时间中位26个月,可能影响结果的普遍性。
  • 骨盆功能不全骨折诊断依赖影像学和随访,未报告盲法或独立中心审核等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the incidence, lesion distribution pattern, and risk factors for pelvic insufficiency fracture (PIF) in cervical and endometrial cancer patients following intensity modulated radiation therapy (IMRT). METHODS AND MATERIALS: In this prospective phase II clinical trial, 113 cervical/endometrial cancer patients who underwent pelvic IMRT at a single hospital (2016-2022) were evaluated. PIF was diagnosed by 2 senior radiologists who were involved in pelvic magnetic resonance imaging, and the results were verified through timely follow-up. RESULTS: Following a median of 26 months of follow-up (range, 14-41 months), the incidence of PIF was 29.2%. The median time to PIF was 8.6 months after IMRT (ranging from 3.5 to 13.5 months). Among patients with PIF, the median number of lesions at initial diagnosis was 2 (range, 1-3); 57.6% were symptomatic, and 66.7% had multiple lesions (≥2). The sacrum (33.3%) and ilium (28.2%) were predominantly involved, with a median lesion area of 1.97 cm2 (range, 0.92-3.28 cm2). The median time to peak total PIF lesion area after radiation therapy was 15.8 months (range, 9.7-22.6 months), and the median number of lesions at that time was 4 (range, 3-5). Postmenopausal state (OR, 18.853; 95% CI, 1.396-254.580; P = .027) and a pre-radiation therapy total procollagen type Ⅰ N-terminal propeptide concentration ≥55 ng/mL (OR, 4.743; 95% CI, 1.257-17.915; P = .022) were independent risk factors for PIF. Neither the PIF area (P = .134) nor the number of PIF lesions (P = .157) was related to the severity of pelvic bone pain. No significant association was found between PIF occurrence and pelvic bone dose-volume parameters, clinical factors (age >53 years, treatment type, osteoporosis), or other biochemical markers (all P > .05). CONCLUSIONS: PIF represents a frequent late complication following pelvic IMRT for cervical and endometrial cancer. It typically manifests as multifocal bone fractures with predominantly mild symptoms, and the total lesion area varies over time. Postmenopausal state and a pre‑IMRT total procollagen type Ⅰ N-terminal propeptide concentration ≥55 ng/mL were independent predictors of PIF occurrence.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Huang Y, Mao D, Chen H, et al. Incidence of and Risk Factors for Pelvic Insufficiency Fracture in Patients With Cervical or Endometrial Cancer Treated With Intensity Modulated Radiation Therapy: A Single-Center, Prospective, Phase II Clinical Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42526655. doi:10.1016/j.ijrobp.2026.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。